Original language | English |
---|---|
Pages (from-to) | 905-908 |
Number of pages | 4 |
Journal | Bone Marrow Transplantation |
Volume | 53 |
Issue number | 7 |
DOIs | |
Publication status | Published - Jul 1 2018 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Hematology
- Transplantation
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Bone Marrow Transplantation, Vol. 53, No. 7, 01.07.2018, p. 905-908.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma
T2 - A decision analysis
AU - Fuji, Shigeo
AU - Kurosawa, Saiko
AU - Inamoto, Yoshihiro
AU - Murata, Tatsunori
AU - Utsunomiya, Atae
AU - Uchimaru, Kaoru
AU - Yamasaki, Satoshi
AU - Inoue, Yoshitaka
AU - Moriuchi, Yukiyoshi
AU - Choi, Ilseung
AU - Ogata, Masao
AU - Hidaka, Michihiro
AU - Yamaguchi, Takuhiro
AU - Fukuda, Takahiro
N1 - Funding Information: Conflict of interest SF received honoraria from Kyowa Hakko Kirin Co., Ltd.; TM is an employee of Crecon Medical Assessment Inc, Tokyo, Japan.; AU received honoraria from Japan Blood Products Organization, Roche Diagnostics, Daiichi Sankyo, Siemens, Bristol-Myers Squibb, Pfizer, Astellas Pharma, Kyowa Hakko Kirin, Novartis Pharma, HUYA Bioscience International, Nippon Shinyaku, Chugai Pharma and Celgene, Immuno-Biological Laboratories, and Sumitomo Dainippon Pharma.; TY had ownership interests of Statcom Co., Ltd., received consulting fee from Ono Pharmaceutical Co., Ltd., received honoraria from Taiho Pharmaceutical Co., Ltd., and received research funding from Kyowa Hakko Kirin Co., Ltd.; MH received research funding from Chugai Pharm Co., Ltd. The remaining authors declare that they have no conflict of interest. Funding Information: Funding This research was partially supported by the Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (15Ack0106136h0002) and the National Cancer Research and Development Fund (26-A-26).
PY - 2018/7/1
Y1 - 2018/7/1
UR - http://www.scopus.com/inward/record.url?scp=85040937123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040937123&partnerID=8YFLogxK
U2 - 10.1038/s41409-017-0082-4
DO - 10.1038/s41409-017-0082-4
M3 - Letter
C2 - 29371687
AN - SCOPUS:85040937123
SN - 0268-3369
VL - 53
SP - 905
EP - 908
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 7
ER -